1.国家自然科学基金面上项目，82370197，SMARCA2低表达介导套细胞淋巴瘤染色体不稳定性的作用及分子机制研究，2024.01-2027.12，在研，主持。

2.国家自然科学基金青年项目，81900203 ，YAP介导套细胞淋巴瘤对伊布替尼耐药的分子机制研究，2020.01-2022.12，结题，主持。

3.国家自然科学基金重点项目，81630007，靶向染色体不稳定关键基因的多发性骨髓瘤多维干预策略实验研究，2017/01-2020/12,275万元，结题，参加。

1. 1.Xiong W, Lv R, Li H,et al. Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. Blood Cancer Journal. 2017 Mar 31;7(3):e548. (IF:12.8)
2. 2.Xiong W, Yu Y, Sun C, et al. Oligosecretory Waldenstrom macroglobulinemia exhibits excellent treatment response and outcomes. Haematologica.2023 Sep 14. (IF:10.1)
3. 3.Xiong W, Wang Z, Wang T, et al. Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia. Front Immunol. 2023 May 10;14:1171539. (IF:8.786)
4. 4.Wenjie Xiong , Tingyu Wang , Ying Yu , et al. Cytogenetic aberrations of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia in Chinese patients. Chin Med J (Engl). 2023 May 20;136(10):1240-1242. (IF:6.1)
5. 5.Shuhua Yi # , Yuting Yan # , Meiling Jin # , Wenjie Xiong , et al. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021 Jan 22.